List of Excipients in Branded Drug CETIRIZINE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing CETIRIZINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
PAI Holdings LLC dba PAI Pharma	cetirizine hydrochloride	0121-0874	ACETIC ACID
PAI Holdings LLC dba PAI Pharma	cetirizine hydrochloride	0121-0874	GLYCERIN
PAI Holdings LLC dba PAI Pharma	cetirizine hydrochloride	0121-0874	METHYLPARABEN

What are the Most Frequently-Used Excipients in CETIRIZINE HYDROCHLORIDE?

# Of NDCs	Excipient
2	.ALPHA.-TOCOPHEROL ACETATE, DL-
8	.ALPHA.-TOCOPHEROL, DL-
8	ACESULFAME POTASSIUM

Last updated: September 24, 2026

Cetirizine hydrochloride is a mature, low-cost antihistamine with limited active-ingredient differentiation but substantial excipient-driven commercial opportunity. The strongest opportunities are taste-masked pediatric liquids and chewables, orally disintegrating tablets, sugar-free and alcohol-free liquids, allergen-conscious formulations, and private-label products with improved stability, packaging, or dosing convenience. Core cetirizine patents and regulatory exclusivities have expired, so market access depends primarily on formulation execution, regulatory compliance, manufacturing economics, branding, and distribution.

Cetirizine Hydrochloride Excipient Strategy and Commercial Opportunities

What is the commercial position of cetirizine hydrochloride?

Cetirizine hydrochloride is a second-generation H1 antihistamine used for allergic rhinitis, chronic urticaria, and related allergy symptoms. In the United States, cetirizine products are marketed primarily as over-the-counter medicines in tablet, chewable tablet, orally disintegrating tablet, and oral-solution formats.

The commercial product has several characteristics that shape excipient strategy:

Attribute	Commercial implication
Mature active ingredient	Limited opportunity for active-ingredient exclusivity
Typical adult strength	10 mg once daily
Pediatric strengths	Commonly 5 mg doses, depending on age and product label
Low unit cost	Manufacturing efficiency is critical
Broad OTC use	Taste, convenience, packaging, and brand positioning influence share
Multiple dosage forms	Excipient selection can create meaningful product differentiation
High generic competition	Formulation patents and trade secrets may be more valuable than composition patents
Strong consumer familiarity	New products must improve convenience or tolerability

The FDA approved cetirizine hydrochloride as a prescription product before its U.S. switch to nonprescription status. FDA approved the OTC switch for Zyrtec in 2007, expanding access and increasing competition from store brands and private-label manufacturers (U.S. Food and Drug Administration [FDA], 2007).

What excipients are used in cetirizine hydrochloride products?

Cetirizine formulations use conventional pharmaceutical excipients. The exact qualitative and quantitative composition varies by manufacturer and dosage form.

Immediate-release tablets

A standard immediate-release tablet may contain:

• Microcrystalline cellulose as a diluent and compression aid
• Lactose monohydrate or another filler
• Povidone as a binder
• Crospovidone or croscarmellose sodium as a disintegrant
• Colloidal silicon dioxide as a glidant
• Magnesium stearate as a lubricant
• Film-coating polymers such as hypromellose
• Titanium dioxide or iron oxides for color, where permitted and commercially desired

A conventional tablet has the lowest technical risk and the lowest development cost. Its commercial disadvantage is weak differentiation. A new product using substantially the same excipient architecture will usually compete on price, retailer placement, packaging, and supply reliability.

Chewable tablets

Chewable cetirizine tablets require more complex excipient design because the product must balance:

• Rapid disintegration
• Acceptable mouthfeel
• Effective taste masking
• Mechanical strength
• Low friability
• Low residual grittiness
• Flavor stability
• Consumer acceptance among children and adults

Common excipient categories include mannitol, sorbitol, xylitol, microcrystalline cellulose, crospovidone, aspartame, sucralose, acesulfame potassium, fruit flavors, and cooling agents.

Mannitol is commercially attractive because it provides a relatively clean mouthfeel and lower hygroscopicity than some sugar alcohols. Sorbitol can improve sweetness and compressibility but may increase hygroscopicity and, at sufficient exposure, gastrointestinal tolerance concerns. Xylitol provides sweetness and a cooling sensation but can increase cost and create supply-chain complexity.

Oral solutions

Cetirizine oral solutions generally use:

• Purified water
• Glycerin or sorbitol
• Propylene glycol, where appropriate
• Sodium citrate or citric acid buffers
• Sodium benzoate or another preservative
• Sweeteners such as sucrose, sucralose, or sodium saccharin
• Flavoring agents
• Colorants, if used

The principal development issues are chemical stability, microbial control, pH, preservative effectiveness, palatability, and dosing-device compatibility. The formulation must also control precipitation and maintain content uniformity throughout shelf life.

Sugar-free and alcohol-free products can address parents seeking pediatric formulations with fewer excipient concerns. They may also be attractive in hospital, institutional, and pharmacy channels.

Orally disintegrating tablets

Orally disintegrating tablets, or ODTs, create a higher-value formulation opportunity. Typical excipient systems include:

• Mannitol or another water-soluble bulking agent
• Crospovidone or sodium starch glycolate
• Low-substituted hydroxypropyl cellulose
• Aspartame, sucralose, or acesulfame potassium
• Flavoring agents
• Colloidal silicon dioxide
• Magnesium stearate

The target is rapid disintegration with limited water, low tablet weight, adequate hardness, and effective taste masking. ODT development can use direct compression, wet granulation, dry granulation, or specialized molding and freeze-drying processes.

The principal risks are bitter taste, moisture sensitivity, tablet friability, and packaging cost. Individual blister packaging may protect the product but can reduce gross margin compared with bottle packaging.

What excipient strategies create the strongest commercial opportunities?

The strongest opportunities are product-positioning opportunities rather than new therapeutic claims.

Pediatric taste masking

Cetirizine has a bitter taste that can limit acceptance in children. Taste masking can use:

• Polymer coating of cetirizine particles
• Ion-exchange resin complexes
• Lipid-based coating systems
• Cyclodextrin complexes
• Sweetener and flavor systems
• Multilayer granules that separate drug release from taste exposure

Ion-exchange resin complexes and coated microparticles can create formulation differentiation. Their commercial value depends on achieving low bitterness without slowing dissolution beyond applicable immediate-release requirements.

A taste-masked liquid or chewable product can command a premium over basic generic tablets if it improves repeat use, reduces caregiver resistance, or supports a branded pediatric positioning.

Sugar-free and low-excipient liquids

Sugar-free liquids can target parents, adult consumers with dietary restrictions, and pharmacy channels that prefer broad-use formulations. The excipient system must control viscosity, sweetness, preservative performance, and palatability without relying on sucrose.

Sorbitol, glycerin, and sucralose are common design tools. The formulation must be assessed for gastrointestinal tolerance, especially where multiple daily products could be used or where consumers have sensitivities to polyols.

Allergen-conscious formulations

“Free-from” positioning can support retail differentiation. Potential claims may relate to the absence of:

• Sucrose
• Alcohol
• Artificial colors
• Lactose
• Gluten-containing ingredients
• Specific preservatives
• Aspartame or phenylalanine sources

These claims require careful regulatory and labeling substantiation. Excipient exclusion can narrow the formulation design space and raise manufacturing cost. The commercial benefit is highest when the claim maps to a clear consumer concern and is visible on the package.

ODT and fast-dissolving formats

ODTs offer a convenient dosage form for consumers who have difficulty swallowing tablets or do not want to carry water. The most commercially practical design is usually a robust, moisture-protected tablet that disintegrates rapidly in the mouth without excessive friability.

ODT products can be positioned for:

• Travel
• Seasonal allergy use
• Adult consumers with dysphagia
• Children able to use solid dosage forms
• On-the-go dosing

The key commercial tradeoff is packaging. Bottles reduce cost but expose the product to humidity. Unit-dose blisters improve protection and portability but increase packaging expense.

What formulation patents and intellectual-property barriers affect cetirizine?

Cetirizine’s basic active-ingredient protection and early U.S. market exclusivity have expired. The original innovator product was Zyrtec, associated with UCB and later commercialized in the United States through other companies. Current generic and OTC competition means that the commercial barrier is not the active ingredient.

Potential intellectual-property protection may still arise from:

• Taste-masked cetirizine particles
• Specific resin-drug complexes
• ODT manufacturing processes
• Coated granules
• Stabilized liquid formulations
• Novel preservative systems
• Dosing devices
• Blister-packaging configurations
• Combination products
• Specific crystalline or particle forms, where legally valid

These rights are narrower than compound patents and may be vulnerable to design-around. A formulation patent is strongest when it links a defined excipient architecture to measurable performance, such as reduced bitterness, improved stability, rapid disintegration, or controlled impurity formation.

Trade secrets may be more valuable than patents for flavor systems, coating parameters, granulation conditions, and manufacturing process controls. Such information can be difficult for competitors to identify from the final product.

What is the FDA regulatory status of cetirizine products?

Cetirizine hydrochloride is marketed in the United States through approved prescription and OTC pathways. OTC products must comply with the applicable FDA monograph framework or obtain an approved application, depending on product type and regulatory route.

Key FDA considerations include:

• Correct active-ingredient strength
• Appropriate age and dosing instructions
• Immediate-release performance
• Stability through labeled shelf life
• Preservative effectiveness for multidose liquids
• Microbial limits
• Excipient safety
• Child-resistant packaging where required
• Accurate Drug Facts labeling
• Compliance with OTC monograph conditions or an approved NDA/ANDA pathway

For an oral solution, preservative effectiveness and microbial control are central. For ODTs and chewables, dissolution, disintegration, friability, content uniformity, and moisture protection require close control.

FDA-approved labels and inactive-ingredient listings should be reviewed before selecting an excipient system. DailyMed provides current labeling and inactive-ingredient information for marketed products, although the database does not replace product-specific regulatory review (National Library of Medicine, n.d.).

How many patents cover cetirizine hydrochloride today?

No meaningful active composition-of-matter exclusivity blocks ordinary cetirizine hydrochloride tablets or liquids in the United States. The original cetirizine patent estate expired years ago, and the product has been subject to extensive generic competition.

The relevant IP analysis for a new product should focus on:

IP category	Current commercial relevance
Original compound patent	Low; expired
Original formulation patents	Generally low unless a specific later patent remains enforceable
Taste-masking patents	Potentially material
ODT patents	Potentially material, depending on claims and jurisdiction
Manufacturing-process patents	Potentially material
Device or packaging patents	Usually narrow but commercially useful
Trademark and trade dress	Relevant for branded OTC products
Trade secrets	Relevant to flavor, coating, and process performance

Patent clearance should cover the United States, European Union, Canada, Japan, Australia, and high-volume emerging markets. Formulation claims may have materially different status by jurisdiction.

When does cetirizine lose exclusivity?

Cetirizine has already lost its principal U.S. exclusivity. The U.S. prescription product entered the market in the 1990s, and Zyrtec became available over the counter in 2007. Generic and store-brand products are widely available.

There is no practical market opportunity based on delaying ordinary generic entry. Commercial value must come from:

• Better dosage form
• Better taste
• Lower manufacturing cost
• Private-label supply
• Retailer exclusivity
• Packaging differentiation
• Combination therapy
• International distribution
• Improved pediatric usability

Because cetirizine is an established OTC ingredient, a product launch generally faces price pressure from major generic manufacturers, mass retailers, pharmacy chains, and established allergy brands.

Which companies are competing in cetirizine products?

The competitive field includes:

• Johnson & Johnson consumer-health brands associated with Zyrtec
• Generic manufacturers such as Perrigo, Teva, and other approved suppliers
• Retailer private-label businesses
• Contract manufacturers producing store-brand tablets, liquids, and chewables
• Regional pharmaceutical companies outside the United States

Competition is fragmented. Brand recognition remains relevant in allergy medicines, but private-label products can compete effectively because cetirizine is familiar and dosing is standardized.

A manufacturer with a lower-cost tablet platform may compete in high-volume retail tenders. A manufacturer with superior taste masking or child-friendly packaging may compete in branded, specialty, or pediatric channels.

What generic launch scenarios exist for cetirizine?

Low-cost tablet launch

This is the lowest-risk scenario but also the most price-sensitive. It requires efficient compression, coating, packaging, and supply logistics. Margins depend on volume and retailer access.

Premium chewable launch

A chewable tablet can support a higher price if taste and mouthfeel are materially better than standard products. The product requires more extensive sensory testing and may face higher excipient and flavor costs.

Pediatric oral-solution launch

A sugar-free, alcohol-free solution with an oral syringe and child-oriented flavor system can target caregivers. Preservative performance and dosing accuracy are central to the product profile.

ODT launch

An ODT can occupy a convenience segment and support premium positioning. Moisture-protective packaging and taste masking are the primary technical barriers.

Private-label platform

One formulation platform can support multiple retailer brands with variations in flavor, color, packaging, and pack size. This model increases manufacturing utilization but shifts bargaining power toward retailers.

How strong is the cetirizine patent estate?

The patent estate is weak for ordinary cetirizine products and potentially stronger for differentiated formulations. A conventional 10 mg tablet using standard excipients is unlikely to support durable exclusivity. A formulation using a specific taste-masking architecture, unusual particle engineering, or a validated stability-enhancing system may have greater protection.

Patent strength should be assessed against five criteria:

1. Claim breadth.
2. Remaining patent term.
3. Enablement and written-description support.
4. Freedom to design around.
5. Ability to detect infringement from the commercial product.

A process patent that cannot be detected from the finished dosage form may have limited practical enforcement value. A composition patent covering a defined coated particle or drug-resin complex is generally easier to assert if the product can be characterized analytically.

What manufacturing and supply-chain barriers affect cetirizine products?

Cetirizine itself is widely available, so supply risk generally centers on excipients, packaging, and manufacturing capacity.

Relevant barriers include:

• Pharmaceutical-grade mannitol and specialty sweeteners
• Taste-masking polymers and ion-exchange resins
• Consistent flavor supply
• Low-moisture ODT production
• High-speed liquid filling
• Blister packaging capacity
• Preservative and microbial-control validation
• Child-resistant closures
• Oral syringe sourcing
• Stability testing under hot and humid conditions

For global commercialization, the formulation should avoid unnecessary excipient complexity. A product that requires a narrow-grade specialty excipient may have superior differentiation but greater supply vulnerability.

What licensing deals are available for cetirizine formulations?

The most realistic licensing opportunities involve:

• Taste-masking technology
• ODT manufacturing platforms
• Pediatric liquid formulation systems
• Drug-resin complexes
• Flavor and sensory technologies
• Private-label supply agreements
• Regional brand licensing
• Contract manufacturing and co-development

Licensing the cetirizine molecule itself offers limited strategic value because the active ingredient is mature and widely available. A licensable platform should demonstrate a measurable advantage, such as lower bitterness, longer liquid shelf life, reduced packaging cost, faster disintegration, or improved stability.

What revenue exposure and commercial upside are realistic?

Cetirizine is a high-volume, low-price product. Revenue exposure is concentrated in unit volume rather than high price per dose. A standard tablet launch may generate limited margin unless the manufacturer has strong retail access or a low-cost manufacturing position.

Higher-value opportunities include:

Product type	Margin potential	Technical risk	Differentiation
Standard tablet	Low	Low	Low
Film-coated tablet	Low	Low	Low
Chewable tablet	Moderate	Moderate	Moderate
Pediatric liquid	Moderate	Moderate	Moderate
Sugar-free liquid	Moderate	Moderate	Moderate
ODT	Moderate to high	Moderate to high	High
Taste-masked pediatric product	High potential	High	High
Private-label platform	Moderate	Low to moderate	Retailer-dependent

The best commercial target is usually a differentiated OTC product that improves use experience without materially increasing cost of goods.

What formulation should a developer prioritize?

A practical development sequence is:

1. Develop a standard immediate-release tablet as a cost benchmark.
2. Screen taste-masking systems for chewable and ODT products.
3. Develop a sugar-free, alcohol-free oral solution.
4. Select packaging based on moisture and stability data.
5. Test multiple flavors with pediatric and adult sensory panels.
6. Evaluate preservative systems and microbial challenge performance.
7. Conduct dissolution and stability comparisons against leading products.
8. Complete patent clearance for formulation, process, packaging, and device claims.
9. Build a private-label and branded commercialization plan.

The most defensible product profile is a 5 mg pediatric dosage form with effective taste masking, a 10 mg adult product in the same platform, and packaging that supports accurate dosing and stable shelf life.

Key Takeaways

• Cetirizine hydrochloride has no meaningful remaining compound-level exclusivity in the U.S.
• Standard tablets are technically simple but commercially commoditized.
• Excipient strategy is most valuable in chewables, liquids, and ODTs.
• Taste masking is the clearest technical route to product differentiation.
• Sugar-free and alcohol-free pediatric liquids offer practical OTC opportunities.
• ODTs can support premium positioning but require moisture protection and sensory optimization.
• Formulation patents, manufacturing know-how, and trade secrets matter more than the expired original compound estate.
• Private-label supply and retailer partnerships may provide more reliable commercial access than a standalone branded launch.
• The strongest platform is a cost-efficient, taste-masked pediatric and adult product family supported by flexible packaging and multiple retail formats.

FAQs

Is cetirizine hydrochloride compatible with lactose-containing tablets?

Yes. Lactose is commonly used as a pharmaceutical diluent, but lactose-free formulations may be preferable for allergen-conscious or differentiated products. Compatibility, moisture exposure, and patient-positioning claims must be assessed at the finished-product level.

Which sweetener is best for cetirizine oral solution?

There is no universal best sweetener. Sucrose provides strong palatability but is unsuitable for sugar-free positioning. Sorbitol, glycerin, sucralose, and combinations of high-intensity sweeteners can support sugar-free products, but each requires evaluation for taste, viscosity, stability, and gastrointestinal tolerance.

Can a cetirizine chewable tablet receive new patent protection?

Potentially. Protection may be available for a novel taste-masking composition, particle coating, drug-resin complex, excipient ratio, or manufacturing process. Ordinary use of known excipients in a conventional chewable is unlikely to provide strong patent differentiation.

What packaging is best for cetirizine ODT products?

Moisture-protective unit-dose blister packaging is generally the strongest technical option. Bottles may lower packaging cost but require effective desiccant and moisture-control systems. The final choice depends on stability, target price, supply-chain conditions, and retailer requirements.

Is a cetirizine combination product commercially attractive?

Combination products can create differentiation, but they also increase regulatory and labeling complexity. Combinations with pseudoephedrine or other allergy ingredients may expand indications and consumer utility, while increasing contraindication, abuse-control, and safety considerations.

References

1. National Library of Medicine. (n.d.). DailyMed: Cetirizine hydrochloride drug labels. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2007). FDA approves over-the-counter Zyrtec for allergies. https://www.fda.gov/

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/

5. U.S. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341